Pharmaceutical companies operate within highly regulated environments and continue to encounter challenges involving trust, governance and scalability as they expand AI adoption across different functions. At the same time, growing data volumes, fragmented systems, and increasing regulatory expectations across clinical development and pharmacovigilance are creating additional complexity throughout the R&D value chain.

TCS ADD™ AgentHub is designed to address these issues by giving organizations a framework where AI agents can function with clear responsibilities, defined oversight, and built-in auditability. Pharma companies can custom build their AI agent hub and deploy them across clinical workflows, while the platform supports rapid and streamlined integration with minimal effort. This approach is intended to accelerate adoption while maintaining regulatory compliance and strengthening the application of AI in drug development.

Operational Gains Across Clinical and Safety Functions

Built on the TCS ADD™ framework, TCS ADD™ AgentHub is designed to deliver measurable operational benefits across drug development and drug safety functions. Solutions powered by the platform have demonstrated up to 40% efficiency gains in clinical data management activities, while metadata-driven automation has enabled up to 30% reduction in clinical study build effort. The platform has also demonstrated up to 30% cost savings in end-to-end safety case processing. In addition, AI-powered safety agents can reduce quality control effort by as much as 50%, supporting productivity improvements across critical R&D processes.

Built on the TCS ADD™ agentic AI architecture, the platform enables pharma companies to deploy a Human + AI Operating Model, embedding AI agents into enterprise workflows while humans continue to retain responsibility for governing and decision-making.

Debashis Ghosh, President, Lifesciences and Healthcare, TCS, said, “TCS ADD™ AgentHub, is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale. It enables a shift from reactive to proactive, scalable, and audit-ready operations amidst an ever-changing regulatory environment. TCS’ strategy is to move towards autonomous enterprise functions where AI agentic workforce operates alongside humans driving innovation in drug development and improving patient safety.”

AI Workers Across Clinical Development and Pharmacovigilance

TCS ADD AgentHub supports workflows across clinical development and pharmacovigilance through AI workers covering ICSR intake, data entry, coding, review, and literature analysis, study design, protocol digitization, and clinical data review, SDTM (Study Data Tabulation Model) transformation, and medical monitoring assistance, among others. The platform has an evolving catalogue of AI agents that can be selected according to specific needs, requirements, and landscape.

These agents can be deployed progressively and rapidly with minimal integration and implementation effort. By standardizing the deployment of AI agents across these processes, TCS ADD™ AgentHub is designed to help organizations improve productivity while enabling scientific teams to concentrate on higher-value work. Buoyed by its comprehensive “AI-first” culture, perfectly exemplified by TCS ADD™ AgentHub, TCS aspires to become the world’s largest AI-led technology services company. By leveraging the proprietary cognitive intelligence of the TCS ADD™ suite, TCS enables tangible, predictive, and secure digital ecosystems for its customers.

Expanding Strategic Collaboration in Life Sciences

This strategic partnership to boost AI drug discovery expands upon an existing foundation between the two organizations. Novo Nordisk already collaborates with Amazon Pharmacy, Amazon Ads, and Amazon One Medical to support how treatments are marketed and delivered to patients. The addition of AWS provides the computational infrastructure necessary to drive operational efficiency and power scientific research across a global workforce of more than 66,700 employees operating in 80 countries.

Co-Innovation Hub at London King’s Cross Facility

To bridge the traditional division between research scientists and technical engineers, the companies are establishing a co-innovation hub within the King’s Cross facility in London. Drug research typically involves separate teams handling hypothesis generation, computational testing, and clinical decision-making, which can lead to operational handoff delays and lost context.

Integrated Technical and Scientific Teams

The London hub unites research and development teams directly with engineers, data specialists, and applied scientists from the AWS Forward Deployed Engineering team and AWS Professional Services organization. By placing computational scientists and clinical researchers in the same physical environment, the initiative aims to shorten the timeline from initial drug target identification to the first human dose. Real-time decision-making allows model engineers and research leaders to refine experimental designs immediately when an AI drug discovery workflow identifies promising candidate molecules.

“By expanding our partnership with AWS, we are creating an environment where our scientists, engineers and technology teams can co-innovate, scale responsibly and accelerate the journey from scientific insight to meaningful outcomes for people living with serious chronic diseases,” said Thilde Hummel Bøgebjerg, Executive Vice President, Enterprise IT & Quality, Novo Nordisk.

Enterprise AI Services Built for Life Sciences

As part of the deployment, Novo Nordisk will integrate purpose-built applications, including Amazon Bio Discovery and Amazon Bedrock AgentCore, across its research, commercial operations, and enterprise IT divisions. Amazon Bio Discovery enables researchers to directly access biological AI models for evaluating and generating candidate molecules. The service bridges computational design with physical laboratory testing via integrated lab partners, creating an iterative experimentation loop to compress early research phases.

Additionally, Amazon Bedrock AgentCore provides infrastructure for AI agents to execute multi-step workflows, reason across enterprise datasets, and integrate with existing systems to improve operational efficiency.

Scaling Enterprise AI Deployments Globally

The initiative builds upon existing technology deployments within the organization. Using Amazon Bedrock, Novo Nordisk previously established a generative AI platform now utilized by more than 25,000 employees. This internal tool allows staff to construct customized chatbots that enhance productivity, assist in document drafting, retrieve corporate information, and support nonregulated workflows.

“Novo Nordisk’s partnership with AWS shows what’s possible when you pair AI with deep life-sciences expertise — removing bottlenecks across drug discovery, not just studying them,” said Dan Sheeran, Vice President and General Manager of Healthcare and Life Sciences at AWS.

“Together, we’re building agentic AI applications that accelerate research, clinical development, manufacturing, and IT operations to help Novo Nordisk move faster end-to-end,” he added.

Living longer, healthier lives has become a global growth market. Behind the capsules and powders marketed under the banner of “longevity” lies sophisticated process engineering. Solutions will be on display at numerous booths at POWTECH TECHNOPHARM in Nuremberg from September 29 to October 1, 2026. For manufacturers of active pharmaceutical ingredients as well as for machinery and plant engineering companies, this opens a market that is still in the early stages of its industrial maturity.

Aging begins at the cellular level. And every cell is a tiny factory with its own power plant, quality control, and recycling facility. Over the years, efficiency declines: power plants falter, waste removal stalls, and spent cells remain on site, disrupting operations. The longevity trend therefore doesn’t start with wrinkles and gray hair, but with the maintenance of the cell itself.

From a Niche Topic to a Billion-Dollar Market

Just a few years ago, “longevity” was a term confined to research labs and California startups. Today, it has become a consumer goods segment experiencing double-digit growth. According to a market study by The Business Research Company, the market for longevity supplements – that is, dietary supplements aimed at healthy aging and cellular function – alone is projected to rise from $8.8 billion in 2025 to $14.3 billion in 2030. If we broaden the market definition to include anti-aging medications, diagnostics, and wellness, forecasts suggest that market volumes will exceed $60 billion over the coming decade.

The most important driver is demographics: The World Health Organization (WHO) estimates that the number of people aged 60 and older worldwide will rise from about one billion in 2020 to approximately 1.4 billion in 2030. Added to this is a shift in mindset. Consumers are increasingly investing in prevention rather than treatment; they are thinking in terms of healthy life years (“healthspan”) rather than just lifespan.

For the process industry, it is not so much the medical hype that is of interest as the question behind it: How are these products actually made? This is where things get exciting for visitors and exhibitors at POWTECH TECHNOPHARM.

The active ingredients and what connects them in terms of process engineering

Four classes of active ingredients dominate the market. NMN (nicotinamide mononucleotide) is a precursor to the coenzyme NAD⁺, which plays a central role in cellular metabolism. Spermidine, found in wheat germ and soybeans, is considered a driver of the cell’s own “garbage disposal” system.

Urolithin A, which is produced in the gut during the breakdown of pomegranate and walnut compounds, is said to trigger the renewal of the cell’s “powerhouses,” the mitochondria. Added to this is the rapidly growing group of senolytics, which are designed to specifically remove old, non-dividing cells from tissue, as well as other NAD⁺ boosters.

What these substances have in common from a process engineering perspective is not their biochemistry, but their production logic. All four represent a shift away from an unreliable, microbiome- or plant-dependent “natural” formation toward controlled, reproducible industrial manufacturing of defined quality. And all four ultimately undergo the same basic process engineering operations that constitute the core business of POWTECH TECHNOPHARM: chemical or biocatalytic reaction, separation and purification, drying into a storage-stable solid, as well as formulation and filling usually as a powder, granule, or capsule.

A clear example is urolithin A: The substance is produced in the human body only if the appropriate gut flora is present – which is not the case for a large portion of the population. Anyone who still wants to reliably offer urolithin A in a defined dose and purity must manufacture it industrially, independent of the microbiome. The Swiss manufacturer Amazentis has described to the U.S. Food and Drug Administration (FDA) a clearly specified manufacturing process for its product Mitopure, featuring high purity urolithin A (purity >97 %), defined limits for impurities, and a final drying step to produce the powder. What began as a metabolic coincidence thus becomes a standardized ingredient in powder form, exactly the kind of challenge for which plant engineers provide process and handling solutions.

Three Paths to the Same Molecule

The process engineering challenge becomes particularly clear when considering NMN. Here, three manufacturing routes are competing in parallel for industrial dominance. Classic chemical synthesis relies on aggressive reagents and precise temperature and humidity control, a complex and expensive process. Microbial fermentation uses genetically engineered bacteria but still struggles with low yields and the problem that common host organisms produce endotoxins, which must be laboriously removed.

The most promising approach at present is enzymatic cascade biocatalysis: multiple tailor-made enzymes convert inexpensive starting materials into the target molecule in a single reaction vessel. The advantages from a process engineering perspective are obvious: mild reaction conditions, high purity, and an aqueous system without the need for complex moisture control. This approach, which marks the actual leap in innovation, is explored in greater depth in a separate article in the Industry Insights section of POWTECH TECHNOPHARM.

In the case of spermidine, extraction from wheat germ, fermentation, and chemical synthesis compete with one another – a textbook example of how the same target substance can be produced via completely different process chains. Which route prevails depends not only on chemistry but also on cost, scalability, and regulatory approval.

The Real Bottleneck: Purification and Formulation

For machinery and plant manufacturers, the opportunity lies not only in the reaction itself but also in the steps that follow. Purification – filtration, chromatography, separation – accounts for a significant portion of manufacturing costs in fermentative and biocatalytic processes, often 15 to 25 percent, and is considered a key bottleneck when scaling up from the laboratory to the production scale. Interesting developments are currently emerging in this area: continuous chromatography and membrane-based separation processes promise significant cost advantages over traditional batch processes. Modular, flexibly configurable plant designs shorten the time to market.

Formulation is at least as important. A highly pure active ingredient is of little use if it breaks down in the digestive tract before it can take effect. That is why techniques are employed that are at the heart of POWTECH TECHNOPHARM: spray drying and microencapsulation for stabilization, liposomal encapsulation for better absorption, along with gentle processes such as spray cooling for temperature-sensitive substances. Wall materials, particle size distribution, flowability, and compressibility for tableting are classic challenges of mechanical and thermal process engineering – only now applied to a new, high-margin product class.

Longevity active ingredients are high-quality solids that must be handled, dosed, mixed, granulated, dried, and filled under GxP conditions, often in small batches, with high purity requirements, and sometimes under containment, because the substances are valuable and, in some cases, highly active. As a result, this topic addresses nearly the entire spectrum of exhibitors at the trade show: from reactor and fermenter construction to centrifuges, filters, and drying systems, as well as mixing, granulation, and tableting technology, containment solutions, and analytics.

Regulations Set Limits

Despite the sense of optimism, a sober assessment is warranted. The regulatory framework in Europe is demanding: NMN, for example, is classified as a “novel food” in the EU and cannot be readily marketed without the appropriate authorization, whereas spermidine-rich wheat germ extract is already approved. For manufacturers, this means that the choice of process and regulatory approval are closely linked. Health-related advertising claims are strictly regulated. And the market forecasts, as enticing as they may sound, are primarily based on commercial studies using varying methodologies – they indicate a trend, not a certainty.

It is this blend of genuine growth and ongoing industrialization that makes the topic attractive to exhibitors and visitors at POWTECH TECHNOPHARM. Longevity is not a mature market where processes have long since been optimized, but rather a field in which active ingredient manufacturers and plant engineers are still jointly developing their solutions. Those exhibiting in Nuremberg or wandering through the halls will find here less of a trendy topic and more of a concrete challenge: turning promising biochemistry into reproducible, safe, and affordable products. This is, in the best sense of the word, a process engineering challenge.

Integrating Experimental and Data Science Capabilities

Under the terms of the agreement, Odyssey Therapeutics will utilize Evotec’s proprietary drug discovery platform. This platform combines extensive compound libraries and advanced screening capabilities with machine learning-driven analysis and AI-enabled data science technologies. By leveraging high-throughput experimentation alongside data-driven insights, the companies seek to discover and validate differentiated small molecule drug candidates across multiple high-value targets.

The approach is designed to accelerate the identification of validated hit series and support the swift progression of early-stage research programs into potential therapeutic options.

Strategic Alignment and Discovery Goals

Speaking on the strategic approach, Evotec Chief Scientific Officer Cord Dohrmann, PhD, noted that drug discovery increasingly relies on uniting deep disease biology with modern experimental platforms.

“This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas,” Dohrmann stated. “We aim to generate differentiated, validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases.”

Through this partnership for autoimmune and inflammatory diseases, both organizations aim to combine complementary technological and scientific capabilities to enhance early-stage drug development. The effort focuses on delivering scalable starting points aimed at advancing future inflammatory disease treatments.

Structure of the Financial Agreement

While specific financial figures were not disclosed, the agreement establishes that Evotec is eligible for milestone payments tied to performance. These payments are contingent upon the successful delivery of validated hit series for each specified target, structuring the collaboration to link value creation directly to drug discovery achievements through their shared drug discovery platform.

Expanding Technological Integration Across Scientific Teams

Under the new arrangement, BMS scientific teams will scale the use of Schrödinger technologies, including the Bunsen AI co-scientist platform and RetroSynth, an AI-driven synthesis planning system. The collaboration aims to enable researchers to explore chemical space more extensively, prioritize molecular candidates with increased confidence, and support decision-making in the early stages of drug discovery.

Bunsen is designed as an agentic AI co-scientist tailored to perform complex workflows in molecular design and computational research. It carries out Schrödinger’s physics-based computational methods, conducts planning and interpretation tasks, and integrates with other research technologies. Complementing this, RetroSynth enables high-throughput evaluation of chemical synthesis planning pathways to evaluate candidate structures efficiently.

Statements from Leadership

Robert Abel, chief scientific officer of the Schrödinger platform, said, “BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery. We are thrilled they are deploying Bunsen at a large scale. Adopting Bunsen and our computational platform at scale will empower a broader group of scientists to embrace a predict-first computational approach.”

Stephen Johnson, vice president of computational sciences at BMS, said, “Over the past several years, AI has become a key enabler for our scientists, allowing them to scale their creativity and scientific expertise across our research organisation. Bunsen is another capability we are adding to that toolkit, one that allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients.”

Core Capabilities and Recent Computational Developments

Schrödinger’s software platform combines artificial intelligence with physics-based simulation to support hypothesis evaluation and synthetic feasibility in molecular research. The organization’s computational solutions are licensed by entities across the global pharmaceutical, biotechnology, industrial, and academic sectors.

In 2026, POWTECH TECHNOPHARM will once again offer ample opportunities for interdisciplinary and international dialogue. In this context, various industry associations are providing inspiration with sessions and events promoting knowledge transfer, networking, and process safety. Delegates at the International Meeting of Bulk Solids Associations on Tuesday, 29 September from 10:00 to 11:00 (NCC Ost, Level 2, New Delhi Room) will gain valuable insights into overseas markets. Representatives of associations from Germany, the UK, the Netherlands and Japan will provide information about business and partnership opportunities. Moreover, the DSIV Process Solutions Pavilion at Booth 7-857 in Hall 7 offers various opportunities to learn about the innovative bulk solids technologies available from DSIV (German Powder and Bulk Association) member companies.

The VDMA Special Show (Booth 7-776 in Hall 7) will feature joint exhibits by its Air Handling Technology and Process Plant and Equipment associations and their member companies. Under the banner “Clean Air – Smart Processing”, the focus this year will be on sustainable, low-emission production and smart, digitally-assisted processing.

Another visitor drawcard that is sure to go off with a bang is the twice-daily live demonstration of dust explosion protection. At midday and in the afternoon, the Rembe Research + Technology Center and the IND EX® Association will carry out impressive demonstrations of the effects of a dust explosion and discuss explosion protection systems. At the IND EX® Explosion Safety Forum from 9:30 to 12:30 on Thursday, 1 October (NCC Ost, Level 2, Riga Room), international specialists can look forward to in-depth professional discussions in an informative programme addressing topics such as practical explosion protection, standards, and new scientific insights from large-scale explosion tests.

Pavilions address growth markets

This year, three pavilions will focus on recycling, pharmaceutical processing technology, and networking with players from key markets like South America and Asia. The pavilion format is well-established at POWTECH TECHNOPHARM and offers an uncomplicated way of participating for exhibitors wishing to showcase their expertise in a particular area in a suitable environment. The Pharma-in-Focus Pavilion is a hub for expertise in pharmaceutical process technology, while the Recycling-in-Focus Pavilion addresses the growing importance of the circular economy and the technologies needed to support it. At the PROCESSING ALLIANCE Pavilion, visitors can network with exhibitors from POWTECH TECHNOPHARM-affiliated events in Brazil, Greece and China while forging international contacts.

Technical innovation takes centre stage at the Young Innovators Pavilion, where startups and fledgling companies showcase their organizations and solutions.

Expert Forum the hub for inspirational ideas, innovations and discussions

The EXPERT FORUM presentations begin every day at 10:00 in Hall 7, Booth 7-489. On Tuesday morning, Wednesday afternoon, and Thursday from 11.30, the focus is on pharmaceutical processing topics. During the sessions, which are moderated by the institutional sponsor of POWTECH TECHNOPHARM, APV (International Association for Pharmaceutical Technology), pharmaceutical industry insiders and experts from various exhibiting companies address a wide range of topics including the characterisation of pharmaceutical materials, virtual planning and optimisation, the use of AI in maintenance, and pharmaceutical freezing processes. Other presentations in the EXPERT FORUM are devoted to overarching issues such as the future of processing, safety and security, smart industry, plant engineering and process technology, and sustainability and energy efficiency. Participants will also gain insights into sustainable energy supply, optimising material flow for tomorrow’s production environment, and AI-assisted machine diagnosis and process management.

From 13:00 to 14:00 on Thursday, the stage is given over to young professionals. At this session organised by the kjVI, the VDI’s network of creative young process engineers, Ida Tolksdorf and Pauline Rust from the VAA (Association of Chemical Industry Managers) will provide tips on first career steps and employment contracts (in German). These presentations are part of the Student Day, which is geared towards all those currently studying or starting out in their careers and is accompanied by special guided tours by the kjVI and young professionals from the DSIV (German Powder and Bulk Association). Students, who enjoy free entry to the fair on Student Day, will learn about innovative technology and the relevant companies from the processing environment, and will have the opportunity to chat with industry experts.

WOMEN4PROCESSING networking event goes into its second round

The WOMEN4PROCESSING networking format for women in the processing industry, which made its debut last year, is now taking place for the second time. Since its launch, women working in industry, academia, R&D, marketing and sales have been able to network through WOMEN4PROCESSING – both online in the associated LinkedIn group and in person again at POWTECH TECHNOPHARM on Wednesday 30 September from 15:30 to 17:00. Prospective members are warmly invited to join the LinkedIn group ahead of the fair to get involved in discussions and obtain their invitation to the next networking meeting.

Good planning is the key to a successful trade fair visit

POWTECH TECHNOPHARM will exhibit a wide range of technologies for processing powders, solids and liquids, including solutions for the GxP-compliant manufacture of pharmaceuticals. Visitors can use the Exhibitor and Product Database beforehand to find relevant products and plan an efficient exhibition walkabout. The results can be filtered not just by product category but also, e.g., by user industry and the various special shows. Information on the programme for the EXPERT FORUM and other highlights is available on the POWTECH TECHNOPHARM website. The wish list function can provide an overview of all relevant exhibitors and topics.

AstraZeneca currently has a market capitalization of approximately 196 billion pounds (approximately 377 trillion Korean won), making it the second-largest listed company on the UK stock market after HSBC, while BMS has a market capitalization of approximately 133 billion dollars (approximately 190 trillion Korean won). Reports indicate that both companies have been holding merger discussions over recent months. Although negotiations could result in an agreement in the near future, there is also the possibility that talks may be delayed or ultimately fail. The structure of the proposed transaction has yet to be finalized, though a combination of cash and stock payments is regarded as the most likely approach for the USD 400B merger.

Combined Cancer Portfolio Would Strengthen Global Market Position

Both AstraZeneca and BMS have built their growth strategies around anticancer drugs, making oncology a central focus of the proposed combination. AstraZeneca’s portfolio includes lung cancer treatment ‘Tagrisso’, breast cancer treatment ‘Enhertu’, and immune-oncology drug ‘Imfinzi’, among others. BMS markets immune-oncology drugs ‘Opdivo’ and ‘Yervoy’, among others. If the companies proceed with the USD 400B merger, the combined business would hold a dominant market share and an extensive pipeline of new drug candidates in the global anticancer drug market.

AstraZeneca was previously the target of a takeover attempt by U.S. Pfizer in 2014, when Pfizer proposed an acquisition valuing the company at approximately 70 billion pounds. AstraZeneca rejected that offer and has since experienced rapid growth driven by its anticancer medicines, reaching an enterprise value approaching 200 billion pounds. Last year, AstraZeneca generated global sales of 58.7 billion dollars and is targeting annual sales of 80 billion dollars by 2030. Nearly half of its current total sales originate from the U.S., the world’s largest pharmaceutical market, and a merger with BMS would further reinforce its business presence there. Meanwhile, BMS continues to face medium- to long-term sales declines resulting from patent expirations of key medications. Although it acquired biotech company Celgene for 74 billion dollars in 2019, the anticipated benefits have not been fully realized, leaving the company seeking new growth drivers and an expanded pipeline of new drugs.

Competition Authorities Expected to Closely Scrutinize Proposed Deal

The most significant challenge facing the proposed USD 400B merger is expected to come from antitrust reviews by competition authorities across multiple countries. Regulatory concerns are likely because the two companies have substantial overlap in their anticancer drug businesses. In particular, BMS’s Opdivo and AstraZeneca’s Imfinzi directly compete in the treatment of non-small cell lung cancer. As a result, competition authorities are expected to closely examine whether combining the two pharmaceutical companies could reduce competition within specific therapeutic markets before any merger is allowed to proceed.

Under the joint $750 million investment by Resilience and Lilly, Resilience’s manufacturing operations in the Cincinnati region will now include production of Lilly’s KwikPen injectable device for innovative medicines used in the treatment of diabetes and obesity. The expansion is expected to generate at least 400 new high-skilled jobs, increasing the total number of Resilience-created jobs in Ohio to more than 1,400 across its facilities. Preparatory work at the expanded campus has already begun, while full operations are scheduled to begin in early 2027.

“We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio,” said William S. Marth, President and Chief Executive Officer of Resilience.

“Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America’s medicine supply,” he added.

Partnership Continues to Expand Domestic Manufacturing Capacity

The long-term manufacturing collaboration between Lilly and Resilience has already resulted in the production of more than 150 million doses of medicines for patients across the United States in vial and pre-filled syringe formats. Together, the organizations have established one of the nation’s largest sterile injectable manufacturing operations, highlighting how trusted U.S. manufacturing partnerships can scale production while maintaining high standards of quality, reliability, and execution. This continued investment also reflects the growing importance of U.S. medicine production as manufacturing capabilities expand to meet rising demand for critical therapies.

Edgardo Hernandez, Lilly’s Executive Vice President and President, Manufacturing Operations, added, “As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today’s announcement highlights Resilience’s role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments.”

“Resilience is an example of Ohio’s emerging leadership in biomanufacturing,” said Ohio Governor Mike DeWine.

Resilience currently operates two advanced facilities in the Cincinnati region that together span nearly 1 million sq. ft. and employ nearly 1,000 Resilience team members across manufacturing, operations, quality, and regulatory functions. The company also recently established its Blue Ash, Ohio location as its global headquarters, underscoring its long-term commitment to the state. The latest announcement also reflects Resilience’s expanding presence in U.S. pharmaceutical manufacturing and its ongoing investment in U.S. medicine production through manufacturing growth in Ohio. In addition, the company’s collaboration with JobsOhio, REDI Cincinnati, and Ohio Life Sciences (OLS) has supported the development of a strong pipeline of high-skilled manufacturing talent across the Cincinnati region.

As AI moves from experimentation to enterprise-wide adoption, healthcare and life sciences organizations are under increasing pressure to deploy trusted AI solutions that improve patient outcomes, accelerate research, enhance operational eficiency, and support clinicians while navigating complex regulatory and ethical considerations.

The AI in Healthcare & Pharma Summit Boston provides a dedicated forum for executives and practitioners to exchange practical insights, learn from real-world deployments, and discuss the opportunities and challenges shaping the future of AI across healthcare and pharmaceutical organizations.

Over two days, attendees will hear from leading experts representing hospitals, health systems, pharmaceutical companies, biotechnology organizations, digital health innovators, research institutions, and healthcare technology providers. Through keynote presentations, technical sessions, interactive panel discussions, and networking opportunities, participants will gain actionable strategies for implementing AI responsibly and at scale.

Key topics include:

• Generative AI in clinical and operational workfows
• AI-powered diagnostics and precision medicine
• Drug discovery and pharmaceutical research
• Machine learning for healthcare decision support
• Responsible AI, governance, and regulatory readiness
• Data quality, interoperability, and healthcare infrastructure
• AI-enabled operational eficiency and workforce transformation
• Emerging technologies shaping the future of healthcare delivery

The summit is designed for senior decision-makers including Chief AI Oficers, Chief Data Oficers, Chief Medical Information Oficers, Chief Digital Oficers, Heads of AI, Data Science Leaders, Clinical Innovation Executives, Healthcare Technology Leaders, Researchers, and Digital Transformation professionals who are leading AI initiatives across healthcare and pharmaceutical organizations.

Beyond the conference programme, the event ofers extensive networking opportunities, enabling attendees to connect with peers facing similar challenges, exchange best practices, and build valuable partnerships across the healthcare AI ecosystem. “The healthcare industry is entering a defning period where artifcial intelligence has the potential to fundamentally reshape how care is delivered, research is conducted, and medicines are developed,” said the event organizers. “The AI in Healthcare & Pharma Summit Boston is designed to bring together the leaders making that transformation happen, creating a space to share practical lessons, collaborate across disciplines, and accelerate responsible AI adoption.”

Organizations interested in showcasing their AI solutions will also have opportunities to engage directly with senior healthcare and pharmaceutical decision-makers through sponsorship, thought leadership sessions, exhibitions, and bespoke networking experiences. The event attracts an audience actively seeking technologies and partners that can help accelerate AI innovation across healthcare and life sciences.

Click here to register

Registration for the AI in Healthcare & Pharma Summit Boston 2026 is now open.

About AI in Healthcare & Pharma Summit Boston

The AI in Healthcare & Pharma Summit Boston is a premier gathering for healthcare, pharmaceutical, AI, data, and technology leaders focused on advancing the responsible adoption of artifcial intelligence across healthcare and life sciences. The summit brings together innovators from hospitals, health systems, pharmaceutical companies, biotechnology organizations, research institutions, and digital health companies to share practical case studies, explore emerging technologies, and build the partnerships driving the future of healthcare.

This agreement marks an important milestone in the development of Global Aviation Africa (GAA), a continental platform dedicated to supporting the modernization of Africa’s airport infrastructure and fostering collaboration among public authorities, airport operators, airlines, investors, and solution providers.

The MoU was signed by Mr. David Wang, Founder, Chairman & Group CEO of MIE Events, and Ms. Daksha Patel, Co-Founder and Managing Partner of Niche Ideas in Dubai.

Under this partnership, Niche Ideas will contribute its international expertise in event development, stakeholder engagement, and the creation of high-value networking platforms for the aviation industry.

Morocco at the Heart of Africa’s Aviation Growth Strategy

This initiative is fully aligned with the enlightened vision of His Majesty King Mohammed VI, whose leadership has positioned Morocco as a strategic gateway between Africa, Europe, and the Middle East.

Through numerous Royal initiatives promoting African integration, infrastructure development, and South-South cooperation, Morocco has established itself as a leading economic and investment hub on the continent and a preferred destination for international investors seeking access to African markets.

The development of the aviation sector and airport infrastructure plays a central role in supporting Morocco’s economic growth, enhancing regional connectivity, facilitating trade and tourism, and strengthening the Kingdom’s position as a key platform for international business and investment.

The decision to launch this initiative in Morocco reflects the Kingdom’s strategic ambition to reinforce its role as a regional and continental hub connecting Europe, Africa, and the Middle East, while serving as a catalyst for innovation, investment, and economic cooperation.

Over the past several months, MIE Events and its Moroccan subsidiary, Global Exhibition Morocco (GEX), have engaged in a series of consultations and meetings with both public and private sector stakeholders across Morocco to explore opportunities for developing this platform within the Kingdom.

These discussions have generated highly positive feedback and resulted in several principle partnership agreements from key organizations operating in the fields of aviation, infrastructure, transportation, investment, and economic development.

Advanced discussions are currently underway with various national institutions to formalize the strategic partnerships that will support the launch of this initiative.

A Platform Dedicated to the Future of African Aviation

Global Aviation Africa aims to become one of the continent’s leading events dedicated to airport infrastructure, aviation innovation, air connectivity, sustainable aviation development, and strategic investment opportunities.

The event will bring together government decision-makers, airport authorities, airlines, international investors, financial institutions, technology providers, and aviation experts from across Africa and around the world.

Through this initiative, MIE Events reaffirms its commitment to supporting the development of Africa’s infrastructure ecosystem while contributing to Morocco’s ambitions in connectivity, investment attraction, and international cooperation.

For more information on Global Aviation Africa, please visit www.gaa-expo.com